ID
22588
Description
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus
Keywords
Versions (1)
- 6/8/17 6/8/17 -
Copyright Holder
Genentech, Inc.
Uploaded on
June 8, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
INVESTIGATOR / SITE CHANGE (UNSCHEDULED) CRFs Roche FVF4168G Macular Edema NCT00473330
INVESTIGATOR / SITE CHANGE (UNSCHEDULED) CRFs Roche FVF4168G Macular Edema NCT00473330
Description
Study administration
Description
INV_NUMBER
Data type
integer
Alias
- UMLS CUI [1]
- C2826689 (Investigator Identifier)
Description
SITE_NUMBER
Data type
text
Alias
- UMLS CUI [1,1]
- C0018704 (Health care facility)
- SNOMED
- 257622000
- LOINC
- LA30302-6
- UMLS CUI [1,2]
- C0600091 (Identifier)
- SNOMED
- 118522005
- LOINC
- LP31795-5
Description
Effective Date of Change: The date of subject’s first contact with the new investigator/site.
Data type
date
Measurement units
- DD/MMM/YY
Alias
- UMLS CUI [1]
- C1302393 (Date of admission)
- SNOMED
- 399423000
Similar models
INVESTIGATOR / SITE CHANGE (UNSCHEDULED) CRFs Roche FVF4168G Macular Edema NCT00473330
C2986440 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,2])
No comments